Selecting Cognitive & Behavioral Endpoint Measures for Trials in...

Selecting cognitive and behavioral endpoints for rare epilepsy and mucopolysaccharidoses (MPS) trials can be challenging. These diseases are often regressive, making the assessment of cognition and...(PRWeb November 05, 2019)Read the full story at https://www.prweb.com/releases/selecting_cognitive_behavioral_endpoint_measures_for_trials_in_rare_epilepsy_and_mps_disorders_upcoming_webinar_hosted_by_xtalks/prweb16698077.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news